Literature DB >> 16527004

Review of adherence to medications for the treatment of osteoporosis.

Deborah T Gold1, Stuart Silverman.   

Abstract

One of the major challenges of successful osteoporosis management is poor patient adherence to current therapies. Individuals who are nonadherent have significant consequences of reduced bone mineral density response, reduced bone marker suppression, and increased risk for fracture compared with individuals who are adherent. Although reducing the dosing interval from daily to weekly oral bisphosphonates has improved adherence, adherence with weekly bisphosphonates remains suboptimal. Barriers to adherence include patient health beliefs, inadequate patient education and age. Potential solutions include increased health care provider-patient interaction, and longer times between doses of medications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527004     DOI: 10.1007/s11914-006-0011-8

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  24 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 2.  Compliance with treatment regimens in chronic asymptomatic diseases.

Authors:  N H Miller
Journal:  Am J Med       Date:  1997-02-17       Impact factor: 4.965

Review 3.  Medication compliance: a healthcare problem.

Authors:  J S Berg; J Dischler; D J Wagner; J J Raia; N Palmer-Shevlin
Journal:  Ann Pharmacother       Date:  1993-09       Impact factor: 3.154

4.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

5.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Authors:  Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

6.  Correlation between patient recall of bone densitometry results and subsequent treatment adherence.

Authors:  Cynthia S Pickney; Jon A Arnason
Journal:  Osteoporos Int       Date:  2005-03-03       Impact factor: 4.507

7.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

8.  Compliance with drug therapies for the treatment and prevention of osteoporosis.

Authors:  Jeffrey S McCombs; Patrick Thiebaud; Connie McLaughlin-Miley; Jinhai Shi
Journal:  Maturitas       Date:  2004-07-15       Impact factor: 4.342

9.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

10.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Authors:  Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

View more
  13 in total

1.  Incorporating adherence into health economic modelling of osteoporosis.

Authors:  O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06-03       Impact factor: 4.507

2.  Patterns of treatment in Australian men following fracture.

Authors:  R Otmar; M J Henry; M A Kotowicz; G C Nicholson; S Korn; J A Pasco
Journal:  Osteoporos Int       Date:  2010-03-13       Impact factor: 4.507

3.  Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

Authors:  Jeffrey R Curtis; Huifeng Yun; Robert Matthews; Kenneth G Saag; Elizabeth Delzell
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

4.  Patient characteristics associated with medication adherence.

Authors:  Sharon J Rolnick; Pamala A Pawloski; Brita D Hedblom; Stephen E Asche; Richard J Bruzek
Journal:  Clin Med Res       Date:  2013-04-11

Review 5.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

6.  Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.

Authors:  J A Sunyecz; L Mucha; O Baser; C E Barr; M M Amonkar
Journal:  Osteoporos Int       Date:  2008-03-20       Impact factor: 4.507

7.  Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Authors:  Jeffrey R Curtis; Qian Cai; Sally W Wade; Bradley S Stolshek; John L Adams; Akhila Balasubramanian; Hema N Viswanathan; Joel D Kallich
Journal:  Bone       Date:  2013-03-15       Impact factor: 4.398

8.  Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial.

Authors:  R Brunner; J Dunbar-Jacob; M S Leboff; I Granek; D Bowen; L G Snetselaar; S A Shumaker; J Ockene; M Rosal; J Wactawski-Wende; J Cauley; B Cochrane; L Tinker; R Jackson; C Y Wang; L Wu
Journal:  Behav Med       Date:  2009       Impact factor: 3.104

Review 9.  Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?

Authors:  Stuart Silverman; Deborah T Gold
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

10.  Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.

Authors:  Jeffrey R Curtis; Juan Xi; Andrew O Westfall; Hong Cheng; Kenneth Lyles; Kenneth G Saag; Elizabeth Delzell
Journal:  Med Care       Date:  2009-03       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.